ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab.

Erin L MacMillan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.